Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for Syndax Pharmaceuticals (SNDX) over the last 7 years, with Q3 2025 value amounting to $2.4 million.

  • Syndax Pharmaceuticals' Amortizatization of Intangibles fell 2109.22% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year decrease of 1304.07%. This contributed to the annual value of $13.5 million for FY2024, which is 901.84% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Amortizatization of Intangibles of $2.4 million as of Q3 2025, which was down 2109.22% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Amortizatization of Intangibles peaked at $4.0 million during Q1 2023, and registered a low of -$187000.0 during Q2 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $2.9 million (2024), whereas its average is $2.1 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 875000.0% in 2021, then soared by 738490.57% in 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at -$171000.0 in 2021, then surged by 1284.21% to $2.0 million in 2022, then skyrocketed by 70.81% to $3.5 million in 2023, then dropped by 15.0% to $2.9 million in 2024, then dropped by 17.93% to $2.4 million in 2025.
  • Its Amortizatization of Intangibles was $2.4 million in Q3 2025, compared to $3.2 million in Q2 2025 and $3.6 million in Q1 2025.